• Solid Tumor Gene Mutation Panel, NGS (Oncotype MAP™, Guardant360® CDx, Guardant Reveal™, PGDx elio™, Northstar Select®, oncoReveal™, LiquidHALLMARK®, PredicineATLAS™, PGDx elio™ Assay)
  • LiquidHALLMARK Multi Cancer Panel
  • LDS
  • Sign up
  • Log in
  • LDS
  • /Medical Tests
  • /Postmeiotic Segregation Increased 2 (PMS2) Gene Mutation Analysis
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References
  • All
  • Diseases
  • Overview
  • Clinical Utility
  • Interpretation
  • Reference Ranges
  • Methodology
  • Specimen Collection
  • Additional Testing
  • Turnaround Time
  • CPT
  • LOINC
  • ICD10
  • Additional ICD10
  • References

Postmeiotic Segregation Increased 2 (PMS2) Gene Mutation Analysis
Medical Test

Turnaround Time
Access to Postmeiotic Segregation Increased 2 (PMS2) Gene Mutation Analysis is restricted.
Loading...